As of 2025-07-03, the Intrinsic Value of DiaMedica Therapeutics Inc (DMAC) is -3.15 USD. This DMAC valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.57 USD, the upside of DiaMedica Therapeutics Inc is -188.19%.
Based on its market price of 3.57 USD and our intrinsic valuation, DiaMedica Therapeutics Inc (DMAC) is overvalued by 188.19%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.15 - -3.15 | -3.15 | -188.19% |
| P/E | (0.76) - (8.25) | (4.60) | -228.8% |
| DDM - Stable | (4.84) - (15.82) | (10.33) | -389.3% |
| DDM - Multi | (0.07) - (0.17) | (0.10) | -102.7% |
| Market Cap (mil) | 153.08 |
| Beta | 1.34 |
| Outstanding shares (mil) | 42.88 |
| Enterprise Value (mil) | 150.51 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.35% |
| Cost of Debt | 5.00% |
| WACC | 10.35% |